DK3305776T3 - Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser - Google Patents

Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser Download PDF

Info

Publication number: DK3305776T3
Authority: DK; Denmark
Prior art keywords: compounds; erk; inhibitors; pharmaceutical compositions; compositions containing
Prior art date: 2004-05-14

Application number

DK17184079T

Other languages

English (en)

Inventor

Gabriel Martinez-Botella

Michael R Hale

Qing Tang

Judith Straub

François Maltais

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-14

Filing date

2005-05-13

Publication date

2019-12-09

2005-05-13 Application filed by Vertex Pharma filed Critical Vertex Pharma

2019-12-09 Application granted granted Critical

2019-12-09 Publication of DK3305776T3 publication Critical patent/DK3305776T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

DK17184079T 2004-05-14 2005-05-13 Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser DK3305776T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US57130904P	2004-05-14	2004-05-14
EP14163944.3A EP2799434B1 (en)	2004-05-14	2005-05-13	Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds

Publications (1)

Publication Number	Publication Date
DK3305776T3 true DK3305776T3 (da)	2019-12-09

Family

ID=35106760

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17184079T DK3305776T3 (da)	2004-05-14	2005-05-13	Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser

Country Status (26)

Country	Link
US (6)	US7354939B2 (da)
EP (5)	EP3305776B1 (da)
JP (1)	JP5132305B2 (da)
CN (1)	CN1976919A (da)
AR (2)	AR051735A1 (da)
AU (1)	AU2005245885B2 (da)
BR (1)	BRPI0511111A (da)
CA (1)	CA2566461C (da)
CY (1)	CY1122336T1 (da)
DK (1)	DK3305776T3 (da)
ES (4)	ES2897422T3 (da)
HK (2)	HK1203505A1 (da)
HU (1)	HUE047130T2 (da)
IL (1)	IL179207A0 (da)
LT (1)	LT3305776T (da)
MX (1)	MXPA06013209A (da)
NO (1)	NO20065727L (da)
NZ (1)	NZ551582A (da)
PL (1)	PL3305776T3 (da)
PT (1)	PT3305776T (da)
RU (1)	RU2376299C2 (da)
SI (1)	SI3305776T1 (da)
TW (1)	TW200607803A (da)
UA (1)	UA84930C2 (da)
WO (1)	WO2005113541A1 (da)
ZA (1)	ZA200609975B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004083203A1 (en) *	2003-03-13	2004-09-30	Vertex Pharmaceuticals Incorporated	Compositions useful as protein kinase inhibitors
WO2005100342A1 (en) *	2004-03-26	2005-10-27	Vertex Pharmaceuticals, Incorporated	Pyridine inhibitors of erk2 and uses thereof
EP3305776B1 (en) *	2004-05-14	2019-09-25	Vertex Pharmaceuticals Incorporated	Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds
US8546404B2 (en)	2005-12-13	2013-10-01	Merck Sharp & Dohme	Compounds that are ERK inhibitors
US7807672B2 (en)	2006-02-16	2010-10-05	Schering Corporation	Compounds that are ERK inhibitors
BRPI0812450A2 (pt) *	2007-06-05	2019-09-24	Schering Corp	derivados de indazol policíclicos e seu uso como inibidores de erk para o tratamento de câncer
CN102015693B (zh)	2008-02-21	2014-10-29	默沙东公司	作为erk抑制剂的化合物
CN102146074B (zh) *	2011-01-26	2013-02-06	江苏先声药物研究有限公司	吡咯衍生物的制备方法及应用
WO2012172093A1 (en)	2011-06-17	2012-12-20	Merz Pharma Gmbh & Co. Kgaa	Dihydroindolizine derivate as metabotropic glutamate receptor modulators
CA2926645C (en)	2013-10-14	2022-10-25	Indiana University Research And Technology Corporation	Use of acamprosate to modulate erk 1/2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd
US20160264536A1 (en)	2013-10-23	2016-09-15	Takeda Pharmaceutical Company Limited	Heterocyclic compound
CA3240745A1 (en)	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Cancer treatment using combinations of erk and raf inhibitors
EP3082423B1 (en)	2013-12-20	2024-12-11	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of cdk and erk inhibitors
WO2015095835A1 (en) *	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers
WO2015095833A1 (en) *	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Treatment of hematologic cancers
EP4389225A3 (en)	2013-12-20	2024-10-09	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of type 2 mek and erk inhibitors
ES2918375T3 (es)	2013-12-20	2022-07-15	Biomed Valley Discoveries Inc	Tratamientos contra el cáncer usando combinaciones de inhibidores de la ruta de PI3K/Akt y ERK
WO2015095831A1 (en) *	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of mtor and erk inhibitors
WO2015095838A2 (en) *	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of mek type i and erk inhibitors
WO2015095842A2 (en) *	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015095807A1 (en) *	2013-12-20	2015-06-25	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of egfr and erk inhibitors
JP7180977B2 (ja) *	2015-01-30	2022-11-30	バイオメッドバレーディスカバリーズ，インコーポレイティド	結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
NZ734041A (en) *	2015-01-30	2022-02-25	Vertex Pharma	Crystalline forms of c21h22cl2n4o2
WO2016187028A1 (en) *	2015-05-15	2016-11-24	Celgene Avilomics Research, Inc.	Heteroaryl compounds, synthesis thereof, and intermediates thereto
US10479791B2 (en) *	2015-06-03	2019-11-19	Changzhou Jiekai Pharmatech Co. Ltd	Heterocyclic compounds as ERK inhibitors
AU2015396809B2 (en) *	2015-06-03	2019-07-11	Js Innopharm (Shanghai) Ltd.	Heterocyclic compounds for treating psoriasis
WO2017068412A1 (en)	2015-10-21	2017-04-27	Otsuka Pharmaceutical Co., Ltd.	Benzolactam compounds as protein kinase inhibitors
EP3170822A1 (en)	2015-11-18	2017-05-24	AGV Discovery	Azaindole derivatives and their use as erk kinase inhibitors
KR20190075931A (ko)	2016-10-05	2019-07-01	제노 로얄티즈 앤 마일스톤즈, 엘엘씨	스피로 고리 화합물
GB201706327D0 (en)	2017-04-20	2017-06-07	Otsuka Pharma Co Ltd	A pharmaceutical compound
WO2019073435A1 (en) *	2017-10-12	2019-04-18	Novartis Ag	COMBINATIONS OF MDM2 INHIBITORS WITH ERK INHIBITORS TO TREAT CANCERS
WO2019180141A1 (en)	2018-03-23	2019-09-26	Bayer Aktiengesellschaft	Combinations of rogaratinib
WO2021020841A1 (en) *	2019-07-29	2021-02-04	Standigm Inc.	Composition for preventing or treating metabolic liver disease
EP4212531A1 (en)	2022-01-14	2023-07-19	AGV Discovery	Azaindole derivatives and their use as erk kinase inhibitors
CN118765276A (zh) *	2022-03-08	2024-10-11	甘李药业股份有限公司	氘代化合物，及其制备方法和应用
CN119212985A (zh) *	2022-03-24	2024-12-27	生物医学谷探索股份有限公司	Erk的吡咯抑制剂的氘代类似物、其合成及其中间体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5716981A (en)	1993-07-19	1998-02-10	Angiogenesis Technologies, Inc.	Anti-angiogenic compositions and methods of use
US5565413A (en) *	1994-12-06	1996-10-15	Zeneca Limited	Substituted pyridyl phenyl ketone herbicides
US5472966A (en) *	1995-03-29	1995-12-05	Bristol-Myers Squibb Company	Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
ATE325114T1 (de) *	1999-06-22	2006-06-15	Takeda Pharmaceutical	Acylhydrazinderivate, verfahren zu ihrer herstellung und ihre verwendung
MY130778A (en) *	2001-02-09	2007-07-31	Vertex Pharma	Heterocyclic inhibitiors of erk2 and uses thereof
AU2003237121A1 (en) *	2002-04-26	2003-11-10	Vertex Pharmaceuticals Incorporated	Pyrrole derivatives as inhibitors of erk2 and uses thereof
US7361665B2 (en) *	2002-07-09	2008-04-22	Vertex Pharmaceuticals Incorporated	Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
US7205298B2 (en)	2002-07-18	2007-04-17	Janssen Pharmaceutica N.V.	Substituted triazine kinase inhibitors
GB0217780D0 (en) *	2002-07-31	2002-09-11	Glaxo Group Ltd	Compounds
NZ538715A (en) *	2002-08-14	2007-07-27	Vertex Pharma	Protein kinase inhibitors and uses thereof
WO2004083203A1 (en) *	2003-03-13	2004-09-30	Vertex Pharmaceuticals Incorporated	Compositions useful as protein kinase inhibitors
EP3305776B1 (en) *	2004-05-14	2019-09-25	Vertex Pharmaceuticals Incorporated	Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds

2005
- 2005-05-13 EP EP17184079.6A patent/EP3305776B1/en active Active
- 2005-05-13 RU RU2006144445/04A patent/RU2376299C2/ru active
- 2005-05-13 BR BRPI0511111-0A patent/BRPI0511111A/pt not_active IP Right Cessation
- 2005-05-13 NZ NZ551582A patent/NZ551582A/en unknown
- 2005-05-13 WO PCT/US2005/016902 patent/WO2005113541A1/en active Application Filing
- 2005-05-13 US US11/128,870 patent/US7354939B2/en not_active Ceased
- 2005-05-13 ZA ZA200609975A patent/ZA200609975B/en unknown
- 2005-05-13 ES ES19199330T patent/ES2897422T3/es active Active
- 2005-05-13 EP EP05748073.3A patent/EP1753738B1/en active Active
- 2005-05-13 ES ES17184079T patent/ES2751761T3/es active Active
- 2005-05-13 CN CNA200580021418XA patent/CN1976919A/zh active Pending
- 2005-05-13 ES ES14163944.3T patent/ES2651439T3/es active Active
- 2005-05-13 ES ES05748073.3T patent/ES2513965T3/es active Active
- 2005-05-13 AU AU2005245885A patent/AU2005245885B2/en active Active
- 2005-05-13 EP EP21190432.1A patent/EP3943489A1/en active Pending
- 2005-05-13 LT LTEP17184079.6T patent/LT3305776T/lt unknown
- 2005-05-13 PL PL17184079T patent/PL3305776T3/pl unknown
- 2005-05-13 MX MXPA06013209A patent/MXPA06013209A/es active IP Right Grant
- 2005-05-13 EP EP14163944.3A patent/EP2799434B1/en active Active
- 2005-05-13 CA CA2566461A patent/CA2566461C/en active Active
- 2005-05-13 AR ARP050101987A patent/AR051735A1/es not_active Application Discontinuation
- 2005-05-13 DK DK17184079T patent/DK3305776T3/da active
- 2005-05-13 SI SI200532267T patent/SI3305776T1/sl unknown
- 2005-05-13 TW TW094115644A patent/TW200607803A/zh unknown
- 2005-05-13 UA UAA200613208A patent/UA84930C2/ru unknown
- 2005-05-13 JP JP2007513432A patent/JP5132305B2/ja active Active
- 2005-05-13 HU HUE17184079A patent/HUE047130T2/hu unknown
- 2005-05-13 PT PT171840796T patent/PT3305776T/pt unknown
- 2005-05-13 EP EP19199330.2A patent/EP3608315B1/en active Active
2006
- 2006-11-13 IL IL179207A patent/IL179207A0/en unknown
- 2006-12-12 NO NO20065727A patent/NO20065727L/no not_active Application Discontinuation
2013
- 2013-08-23 US US14/544,396 patent/USRE46097E1/en active Active
2015
- 2015-05-04 HK HK15104226.1A patent/HK1203505A1/xx unknown
2016
- 2016-06-28 US US15/195,021 patent/USRE47318E1/en active Active
- 2016-11-18 AR ARP160103545A patent/AR106755A2/es active IP Right Grant
2018
- 2018-05-15 HK HK18106295.9A patent/HK1247910A1/zh unknown
2019
- 2019-03-25 US US16/363,905 patent/USRE48266E1/en active Active
- 2019-12-03 CY CY20191101265T patent/CY1122336T1/el unknown
2020
- 2020-10-15 US US17/071,566 patent/USRE49500E1/en active Active
2023
- 2023-02-22 US US18/173,004 patent/US20230183276A1/en active Pending

Also Published As

Publication number	Publication date
BRPI0511111A (pt)	2007-11-27
CA2566461C (en)	2012-07-10
AR051735A1 (es)	2007-02-07
EP3305776B1 (en)	2019-09-25
US20230183276A1 (en)	2023-06-15
MXPA06013209A (es)	2007-01-16
RU2376299C2 (ru)	2009-12-20
EP3305776A1 (en)	2018-04-11
RU2006144445A (ru)	2008-06-20
JP2007537295A (ja)	2007-12-20
USRE46097E1 (en)	2016-08-09
EP1753738B1 (en)	2014-07-09
ES2513965T3 (es)	2014-10-27
ES2751761T3 (es)	2020-04-01
HK1203505A1 (en)	2015-10-30
USRE47318E1 (en)	2019-03-26
NO20065727L (no)	2006-12-12
EP3608315B1 (en)	2021-08-11
IL179207A0 (en)	2007-03-08
EP3943489A1 (en)	2022-01-26
US20060106069A1 (en)	2006-05-18
CA2566461A1 (en)	2005-12-01
PT3305776T (pt)	2019-12-17
HUE047130T2 (hu)	2020-04-28
JP5132305B2 (ja)	2013-01-30
EP3608315A1 (en)	2020-02-12
AR106755A2 (es)	2018-02-14
ZA200609975B (en)	2008-02-27
NZ551582A (en)	2011-01-28
TW200607803A (en)	2006-03-01
CN1976919A (zh)	2007-06-06
LT3305776T (lt)	2020-01-10
USRE48266E1 (en)	2020-10-20
EP1753738A1 (en)	2007-02-21
EP2799434B1 (en)	2017-08-02
SI3305776T1 (sl)	2020-01-31
UA84930C2 (ru)	2008-12-10
PL3305776T3 (pl)	2020-03-31
ES2651439T3 (es)	2018-01-26
USRE49500E1 (en)	2023-04-25
AU2005245885B2 (en)	2011-01-20
CY1122336T1 (el)	2021-01-27
ES2897422T3 (es)	2022-03-01
AU2005245885A1 (en)	2005-12-01
EP2799434A1 (en)	2014-11-05
HK1247910A1 (zh)	2018-10-05
WO2005113541A1 (en)	2005-12-01
US7354939B2 (en)	2008-04-08

Publication	Publication Date	Title
DK3305776T3 (da)	2019-12-09	Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser
DK1713806T3 (da)	2013-08-05	Forbindelser og sammensætninger som proteinkinaseinhibitorer
DK1664043T3 (da)	2008-03-25	Sammensætninger egnede som inhibitorer af proteinkinaser
DK1888584T3 (da)	2010-08-09	Tricykliske 1,6-dihydro- 1,3,5,6-tetraaza-as-indacen-baserede forbindelser og farmaceutiske sammensætninger omfattende samme som hæmmere af IKK-enzymaktivitet
DK2076260T3 (da)	2011-06-27	N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse
DK1562589T3 (da)	2009-02-16	Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
DK1962830T3 (da)	2013-06-24	Azaindolhæmmere af aurorakinaser.
DK2039685T3 (da)	2013-03-25	Heterobicycliske forbindelser som P38-inhibitorer
DK1928879T3 (da)	2013-05-21	Kondenserede heterocykliske forbindelser og anvendelse heraf som kinase-modulatorer
NO20082256L (no)	2008-07-15	Pyrazolderivater, preparater som inneholder slike forbindelser, og fremgangsmåter for anvendelse
DK1848694T3 (da)	2010-01-25	Heterocykliske substituerede phenylmethanoner som inhibitorer af glycintransporter
DE602005025733D1 (de)	2011-02-17	Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
DK1756064T3 (da)	2008-09-22	Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder
DK1945631T3 (da)	2012-10-22	4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
DK1480644T3 (da)	2011-01-24	Heterocykliske forbindelser, der er aktive som inhibitorer af beta-lactamaser
DK1789041T3 (da)	2008-09-08	Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1730146T3 (da)	2011-08-15	Azaindoler anvendelige som inhibitorer af JAK og andre proteinkinaser
DK1711481T3 (da)	2010-04-19	Fremgangsmåde til fremstilling af 2-aminothiazol-5-aromatiske carboxamider som kinaseinhibitorer
DK1758914T3 (da)	2008-03-17	Hidtil ukendte fluorglycosidderivater af pyrazoler, lægemidler indeholdende disse forbindelser og anvendelse heraf
DK1877232T3 (da)	2014-08-11	Fremgangsmåde til behandling af træoverflader
DK1585749T3 (da)	2008-09-22	Diazepinoindol-derivater som kinaseinhibitorer
SE0701538L (sv)	2007-06-26	Azaspiroalkanderivat som hämmare av metalloproteaser
DK2021335T3 (da)	2011-09-05	Heterocykliske forbindelser som C-FMS-kinasehæmmere
DK1761505T3 (da)	2011-12-05	Pyrimidin-urinstof-derivater som kinaseinhibitorer
DK1786785T3 (da)	2010-05-31	Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere